| INTRODUC TI ON
Variability and dysfunction in pigment-producing melanocytes lead to considerable consequences for both human and animal physiology. We describe emerging frontiers in clinical and basic research of normal and diseased melanocytes that impact current approaches to research in melanoma and the dermatological sciences. We focus on four themes, organized in corresponding sections: (1) clinical melanoma research, (2) basic melanoma research, (3) clinical dermatology, and (4) basic pigment cell research, with the goal of outlining current highlights, challenges, and frontiers associated with pigmentation and melanocyte biology.
The council of the Pan American Society for Pigment Cell Research has summoned a comprehensive assessment of the current state of progress in melanoma research and dermatological sciences. Intensive discussions among members of the International Federation of Pigment Cell Societies (IFPCS), the International Pigment Cell Conference (IPCC), 1 the Society of Melanoma Research (SMR) 1 , the Skin of Color Society (SOCS), and the Melanoma Prevention Working Group (MPWG) nucleated this perspective and culminated in the current status, challenges, and opportunities of respective thematic research areas (Box et al., 2018) . The scope of this perspective was to highlight emerging trends in the four thematic areas, rather than aiming for exhaustive completeness, with a few citations limited to those appearing in the past 12 months.
In the field of clinical melanoma, mechanistic understanding based on genomic and immunological data has led to extraordinary recent progress in diagnosing and treating melanoma tumors. In clinical dermatology, loss of normal pigmentation is mediated by inflammatory, immunological, and genetic determinants. Vitiligo management innovates by reversing skin disease through suppression of autoimmune inflammation and promoting melanocyte regeneration. Progress in management of albinism includes providing precise molecular definition of underlying genetic mutations, limiting ultraviolet (UV) light exposure by physical barriers, and in the future support by pharmacologic and genetic intervention. In melasma and hyperpigmentation areas, the frontlines are molecular understanding of pathogenesis and systematic evaluation of which combinations of topical, oral, and procedural therapies are most effective in treating postinflammatory hyperpigmentation. In basic melanoma and dermatology research, current frontiers include understanding of genomic profiles, signaling pathways, and biophysics of melanins to arrive at comprehensive insights into developmental and biomedical properties of pigment cells.
| RE SULTS AND D ISCUSS I ON

| Section 1-Clinical melanoma research
| State of the art of immunotherapy of malignant melanoma
Immunotherapy has moved to center stage in melanoma treatment with the recent success of trials involving blockade of immune checkpoints (Weber et al., 2017) . The cytotoxic T lymphocyte-associated antigen 4 (CTLA4, CD152), and the combination of programmed death 1 (PD-1, PDCD1, CD279) and programmed death 1 ligand (PD-L1, PDCD1L1, CD274) comprise immune checkpoints and negative regulators of T cell immune function. The roles of CTLA4 and PD-1 in inhibiting immune responses, including antitumor responses, are largely distinct. CTLA4 can regulate T cell proliferation early in an immune response, primarily in lymph nodes, whereas PD-1 suppresses T cells later in an immune response, primarily in peripheral tissues.
Inhibition of these targets has provided successful modes of intervention, leads to increased activation of the immune system, and has led to new immunotherapies for melanoma and other cancers.
Ipilimumab, an inhibitor of CTLA4, is approved for the treatment of advanced or unresectable melanoma. Nivolumab and pembrolizumab, both PD-1 inhibitors, are approved to treat patients with advanced or metastatic melanoma and patients with metastatic, refractory non-small-cell lung cancer. In addition, the combination of ipilimumab and nivolumab has been approved in patients without B-Raf proto-oncogene, serine/threonine kinase (BRAF) activating mutations and metastatic or unresectable melanoma. Checkpoint regulators on T cells play vital roles in limiting adaptive immune responses and preventing autoimmune and auto-inflammatory reactivity in the normal host (Najjar et al., 2017) . In cancer patients, PD-1 expression can be very high on T cells in the tumor microenvironment, and PD-L1, its primary ligand, is variably expressed on tumor cells and antigen-presenting cells within tumors, providing a potent inhibitory influence within the tumor microenvironment. While PD-L1 expression on tumors is often regarded as a negative prognostic factor, it can be associated with a positive outcome for treatment with PD-1/PD-L1 blocking antibodies and has been used to select patients for this therapy. Therapy regimens with immune checkpoint blocking antibodies are characterized by responses of long duration, while a minority of patients displays atypical responses. In such cases, progression may precede tumor shrinkage, and a pattern of autoimmune side effects is associated with this class of drugs. Even though excellent efficacy and some complete remissions have been seen in a limited number of melanoma patients, some of whom may be regarded as cured of cancer, many malignancies do not show responses of long duration with these agents. Predicting tumor responses to immune checkpoint blockade remains a major challenge and an active field of research fueled by systems biology data.
| Targeted therapy, combination therapy and treatment resistance
Inhibition of the mitogen-activated protein kinase (MAPK) pathway using BRAF kinase inhibitors or MAP2K (MEK1/2) inhibitors as single agents improves survival of patients with BRAF(V600E)-mutant metastatic melanoma compared with standard chemotherapy.
Although BRAF-activated melanomas have initially been the most responsive melanoma subset due to targeted therapies, patients ultimately develop resistance. Accordingly, there is now rapid progress in combinatorial therapeutic approaches, especially ones taking advantage of engaging the immune system to fight cancer cells.
Concurrent BRAF and MEK inhibition improved clinical outcomes further over single-agent BRAF inhibitors, with decreased toxicities related to paradoxical activation of the MAPK pathway in BRAF wildtype cells (Dummer et al., 2018) . More than 95% of patients experienced tumor reduction when treated with MEK inhibitors dabrafenib and trametinib in combination. Although 50% of patients showed disease progression after 12 months, a fraction of patients experienced long-term progression-free survival. The future selection of patients for combined BRAF and MEK inhibition, and the rational design of clinical trials for those who fail this combination will be as- specific therapeutic responses will have a major impact on defining an optimal fit for a growing spectrum of targeted therapeutic treatments and schedules.
| Melanoma heterogeneity in progression and therapy resistance
Identification of precision medicine profiles and stratification of skin cutaneous, uveal, mucosal, and acral melanoma are a defined goal of the melanoma research community (Filipp, 2017; Hayward et al., 2017) . In melanoma patients, tumor cells activate pathways common to proliferating fibroblasts, endothelial cells, or even inflammatory and immune cells. Tumor cell surface receptors and tumor-secreted proteins are associated with mitogenic and proliferative signaling, migration, invasion, and antiapoptosis. In addition, there is a group of molecules that is not associated with the phenotype of differentiated melanocytes in the skin or surrounding fibroblasts or stroma but that represents re-expressed developmental genes. Several developmental pathway genes, such as those associated with neurotrophin signaling, noncanonical WNT, or NOTCH signaling, are commonly expressed by melanocyte precursors, stem cells of the dermis, and by melanoma cells. However, they are absent in epidermal melanocytes. In the future, systems biology approaches including large-scale omics platforms or computational models will provide mechanistic insight into melanoma heterogeneity and therapy resistance (Krepler et al., 2017; Zecena et al., 2018) .
| Melanoma prevention and epidemiology
Melanoma is a cancer with globally increasing rates. Regions most affected are those predominantly populated by individuals of European ancestry and lighter pigmentation. Across all populations, there are differences in melanoma incidence and mortality by gender and age. In general, melanoma incidence correlates with cumulative UV exposure and is therefore a function of age. However, while there is a greater incidence in older males than females of the same age group, such a trend appears to be reversed earlier in life, pointing to genetic-epidemiological associations. Across the continents, the highest incidence is found in Australia (up to 40 per 100,000) followed by Northern America and Europe (>10 per 100,000). Rare cases (<0.5 per 100,000) are observed in Asia and Africa. Efforts comprise primary prevention-above all-in children and adolescents aimed at reducing harmful UV exposure to prevent the initiation of carcinogenesis. Secondary prevention is focused on screening and early detection of disease or precursor lesions. Lastly, tertiary prevention is aimed at recurring or second primary incidences of disease in combination with targeted chemopreventive efforts in high-risk populations. The multidisciplinary group dedicated to melanoma prevention includes patient advocates, melanoma foundation leaders, basic scientists, epidemiologists, bioinformaticians, social psychologists, and clinician-investigators from dermatology, dermatopathology, medical oncology, surgical oncology, and radiation oncology. Going forward, collaborative efforts are focused on incorporating training and education, smartphone app-based image acquisition, big data-driven technologies, and machine-learning into melanoma prevention and early detection efforts. Vdr knockout mouse models are opiate-seeking. The latter phenotype could be rescued by vitamin D supplementation, suggesting a connection between UV, vitamin D metabolism, and opiate signaling.
| Section 2-Basic melanoma research
| Oncogenic signaling in melanoma
| Animal models
Animal models continue to contribute critically important insights into pigment cell and melanoma biology (Aktary, McMahon, & Larue, 2018 The recent emergence of CRISPR/Cas9-based genetic engineering approaches has changed the approach to and design of new animal models. These tools are being adapted by a large number of laboratories, and enable somatic genetic editing in both in vitro and in vivo screens with efficiencies that have not been possible previously. is much more common in sub-Saharan Africa. People with albinism experience visual deficits, hypopigmentation, and sun sensitivity. In less advanced societies, people with albinism may not have access to healthcare specialists, sunscreen, or protective clothes. Patients are prone to sunburns and UV-dependent skin cancers, particularly in regions with a high UV index. If not removed in a timely manner, these skin cancers can eventually metastasize and cause premature death, often before the age of 40. Sadly, patients with albinism in Africa face a humanitarian crisis. This crisis stems from a lack of access to resources and an alarming increase in ritual assassinations of people with albinism (Franklin, Lund, Bradbury-Jones, & Taylor, 2018) . The united pigment cell community stands in solidarity and supports patients suffering from albinism, leaving a unique footprint in the field of pigment cell biology. Perilesional skin biopsies from Sinclair swine vitiligo lesions respond to DNA vaccination with a melanocyte antigen sufficient to drive autoimmunity and provide a unique opportunity to study the process of repigmentation in animal-derived skin with human-like properties. A new method for studying the cellular and molecular foundation of vitiligo was presented by combining immunostaining with laser capture microdissection to define the number and phenotype of melanocyte stem cell populations in the hair follicle bulge during narrowband UVB treatment of vitiligo patients (Goldstein et al., 2018) . This strategy facilitates identification of pathways that govern repigmentation in human vitiligo.
| Section 3-Clinical dermatology
| Clinical research advances on albinism
| Progress in clinical and basic research of the autoimmune disease vitiligo
Currently, clinical dermatologists have the opportunity to build on successes of melanoma research, largely through understanding immune checkpoint pathways. By building on existing genomic profiles and by connecting immunological signatures of melanocytederived samples with patient and context-specific questions, dermatological subdisciplines have the potential to rapidly translate molecular insights into the clinic.
| Progress in vitiligo genetics
Genomewide association studies have discovered approximately 50 genetic loci contributing to vitiligo risk in European-derived Caucasians. For many of these vitiligo susceptibility loci, the relevant causal gene and DNA sequence variants have been identified. Corresponding genes are involved in immune and apoptotic regulation, melanocyte function, and autoimmune targeting (Spritz & Andersen, 2017) . Study of population isolates with a high preva- Chemically excited electrons take on a key role in photoproduct formation after UV irradiation. During UV exposure, cyclobutane pyrimidine dimers (CPDs) are created by coordinated opening of two double bonds on adjacent pyrimidine bases (thymine or cytosine) to join the bases in a cyclobutane ring, a reaction possible only after an electron has been excited. Extraordinarily high energies during UV exposure are accompanied by electron excitation and drastically altered orbital shapes, allowing reactions that quantum mechanics otherwise forbids. CPDs then lead to the UV signature mutations underlying melanoma and other skin cancers. Surprisingly, melanocytes were discovered to also generate CPDs for hours after UV exposure ended. Such dark CPDs constituted the majority of CPDs in human melanocytes in vitro and mouse skin and were most prominent in skin containing pheomelanin. The mechanism was found to be excitation of an electron by a chemical reaction involving melanin, superoxide, and nitric oxide, rather than by a photon. Chemiexcitation is familiar in fireflies but was unknown in mammals. Evidently, melanin is carcinogenic as well as protective. Chemiexcitation is therefore a new mode of pathogenesis that contributes to the CPD footprint known to result in UV signature mutations in melanoma genomes. The process may also underlie diseases in tissue never exposed to UV: Inflammation generates superoxide and nitric oxide and these three factors colocalize with melanin or neuromelanin in tissues susceptible to macular degeneration, noise-induced deafness, and Parkinson's disease. 
| Section 4-Basic pigment cell research
| Photochemistry and pathophysiology of pigments
| Genetics of pigmentation
Recent advancements in genomic profiling reveal that homologous genes in humans are not only involved in pigmentation disease but also determine skin and hair color in vertebrates. In addition, the field of pattern formation includes the attractive study of how genetic variation influences gradients of pigment factors. Comparative animal models together with human genetics are utilized to study the evolution of pigmentary systems. Work on coat pattern formation using the African striped mouse shows how dorsal racing stripes are established in rodents, others mammals, and fish. Using the Zebrafish as a model system, it is possible to study the long-distance influence macrophages play in adult pigmentation pattern development.
It is essential to understand the molecular, cellular and genetic foundations of these patterns that are common across species to help understand the evolutionary processes under phenotypic selection. The transcription factor ALX homeobox 3 (Alx3) was identified as a primary regulator of melanocyte maturation through the pattern of expression in the embryo via inhibition of the melanogenesis associated transcription factor (Mitf) gene within the melanocyte, thereby suppressing pigmentation and giving the appearance of light-colored hair (Mallarino et al., 2016) . Notably, chipmunks have independently evolved a similar dorsal light stripe pattern through ALX3 regulation of MITF. The contribution of agouti signaling protein (Asip) as a differentially expressed gene in the patterning process is yet to be fully defined. In human populations, where pigmentation is studied as a variable trait, most interest has focused on why lighter populations arose from darker ancestors upon leaving Africa. Recent genomic insights revealed the distribution of skin colors in African and human ancestral populations. The architecture of skin pigmentation showed unprecedented variation across human populations and revealed different evolutionary influences. Similar mechanisms, gradients of pigmentation, and selection pressures applied to Africans and Europeans. Genetic evidence indicated that the light pigmentation variant at melanosome solute carrier SLC24A5 was introduced into the Eastern African population by gene flow from non-Africans (Crawford et al., 2017; Martin et al., 2017) . The rs1426654 (L374F) change has a big effect on skin type in Europeans. However, it was unexpected that this allele seems to have gone back into African populations and is also driving lighter skin across these populations.
Other notable findings are the involvement of hitherto unreported genes in pigmentation variation. These are Mfsd12, confirmed by testing in animal models, that is, mouse grizzled coat color, and associated with dark skin; Ddb1/Tmem138, increased expression suggests increased DNA repair being associated with pigmentation responses. The identified SNPs still only explain about 30% of the variance seen in understudied African pigmentation, so other genes remain to be discovered. Currently, the UK Biobank, with more than 500,000 individuals, provides the widest range of pigmentation genotype-phenotype interactions characterized so far.
Human genetic information has potential for implementation into the dermatology clinic for the delivery of personalized medicine.
Difficulties and challenges of germline genomic analysis of patients at high risk of melanoma have to be carefully taken under consideration.
Using cultured clonal human melanocytes as a model system, the effect of transcription factor interferon regulatory factor 4 (IRF4) in pigmentation biology and interferon-gamma response is under investigation.
Congenic cultures with homozygous allele variation in an IRF4 intronic regulatory region differed with respect to expression of chemokines and immune checkpoints, CCL3, CCL5, CTLA4, and PD-L1.
| CON CLUS ION
Shared success and progress of the pigment cell research community in understanding of cellular and immunological homeostasis of pigment cells but also clinical challenges and hurdles in the treatment of melanoma and dermatological disorders continue to drive future research activities. Investigators in the pigment cell research community have diverse but complementary backgrounds, and include chemists, physicists, basic biological scientists, dermatologists, surgeons, oncologists, epidemiologists, bioinformaticians, and biomedical engineers. The cross-disciplinary nature of the field is unique, unified around a passion for understanding the establishment and maintenance of normal pigmentation, and benign or malignant pigmentary diseases. This fosters the generation of new translational research ideas crossing multiple disciplines.
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